[MSB-12] Our Clinical Experience with Septal Myectomy in Hypertrophic Cardiomyopathy Patients

Objective: This study aimed to share our surgical experience of patients with hypertrophic cardiomyopathy (HCM) treated successfully with surgical myectomy at a tertiary center that frequently utilizes minimally invasive approaches in clinical practice. Methods: This study was conducted with eight patients (5 males, 3 females; mean age: 49.2±12.5 years) patients who underwent surgery for HCM between 2017 and 2024. Results: All patients were symptomatic. Four of the patients had concomitant mitral valve pathologies requiring surgery, with one patient also having aortic valve pathology. Preoperative mean gradients were 49.1±22.8 mmHg at rest and 102.8±27.2 mmHg with the Valsalva maneuver. One surgery was performed via sternotomy. Two patients were operated on with anterolateral thoracotomy technique and five with a minimally invasive robotic approach. Four patients underwent isolated myectomy. The mean cardiopulmonary bypass time was 165.5±53.8 min, and the mean cross-clamp time was 112.1±42.5 min. No intraoperative complications were observed. A third-degree atrioventricular block, which was treated with an implantable cardioverter-defibrillator, was the only postoperative complication. The mean hospital stay was 7.5±2 days, with a mean intensive care unit stay of 2.38±1.77 days. Conclusion: Hypertrophic cardiomyopathy is a genetic cardiac disorder with a heterogeneous spectrum of clinical manifestations. Septal reduction therapies are the primary treatment for patients. Septal myectomy has been shown to be effective, providing a reduction in outflow tract gradient and symptoms. Currently, myectomy is the recommended treatment for HCM, and it can be performed via conventional median sternotomy or minimally invasive approaches.